Patients with glioblastoma have very poor prognosis since there are no effective therapies. In a study published in Cell Reports, researchers have discovered a correlation between the cell type from which the tumor originates and the growth and drug sensitivity of the tumor. More knowledge about the mechanisms behind this correlation could be important for developing more effective drugs against subgroups of glioblastoma.
Glioblastoma is the most common form of primary brain tumour in adults and is essentially lethal. Presently, the development of more effective therapies is hampered by the large degree of tumor heterogeneity, both between different patients and in a single tumor. The heterogeneity between different tumors is partly due to the fact that the tumor can originate from different kinds of brain cells. The tumor's cell of origin can be either an immature neural stem cell or a more differentiated glial cell.
To develop improved therapies for glioblastoma, more knowledge is needed about how the cell of origin affects the characteristics of the cancer cells. Such studies must initially be performed in mice since it is not possible to identify the cell of origin in patient material. In the present study the researchers used several clinically relevant glioblastoma models in mice and found that tumors that originated from immature neural stem cells developed faster than tumors that originated from more differentiated glial cells.
"We discovered that several important characteristics of the cancer cells could be linked to the tumor's cell of origin. Immature neural stem cells gave rise to glioblastomas that grew faster and were more malignant than those that originated from glial cells. Tumors from neural stem cells also contained more glioblastoma stem cells, cells that are believed to give rise to tumor recurrence after therapy," says lead author of the study.
To determine how the cell of origin affected the characteristics of glioblastoma cells, the researchers analyzed how the activity of a large number of genes differed between tumors with different origins. They were able to identify a 'gene signature' of almost 200 genes.
"When we compared the gene signature activity of glioblastoma cells from around 60 patients we found that a large number of patients could be divided into subgroups that showed a correlation between gene activity, tumor cell characteristics and cell of origin similar to the one we had seen in the mice study. This indicated that the cell of origin also has a direct influence on the characteristics of human tumours," says the lead author.
One feature of the tumor cells that the researchers were particularly interested in was their sensitivity to cancer drugs, and here too they found a correlation with the cell of origin. Glioblastoma cells from patients that could be linked by the gene signature analysis with an immature origin generally showed a higher sensitivity to cancer drugs than glioblastoma cells that were associated with a more differentiated cell of origin.
"We show that the cell of origin is important for the malignancy and drug sensitivity of glioblastoma cells, and that the findings can also be applied to glioblastoma cells from patients. We hope the gene signature we identified can provide the basis for an improved classification of glioblastoma patients and for identifying new targets for therapy," says the lead author.
Cell of origin affects malignancy and drug sensitivity of brain tumors
- 2,241 views
- Added
Edited
Latest News
Ancient viral DNA in the hu…
By newseditor
Posted 26 May
AI to analyze clumping prot…
By newseditor
Posted 26 May
Reversible, non-hormonal ma…
By newseditor
Posted 26 May
Dissection of the schizophr…
By newseditor
Posted 26 May
Protease action on controll…
By newseditor
Posted 25 May
Other Top Stories
Check-point inhibitors exacerbate NASH induced liver cancer
Read more
AI used to understand asbestos-linked cancer
Read more
Protein rewires cancer cell metabolism to promote metastasis
Read more
The role of hypoxia-inducible factors in tumor growth and suppression
Read more
Dual treatment to kill small cell lung cancer (SCLC) cells
Read more
Protocols
SEMORE: SEgmentation and MO…
By newseditor
Posted 26 May
Spatially resolved lipidomi…
By newseditor
Posted 24 May
Efficient expansion and CRI…
By newseditor
Posted 21 May
Massively parallel in vivo…
By newseditor
Posted 20 May
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Publications
Integrating human endogenou…
By newseditor
Posted 26 May
The thalamic reticular nucl…
By newseditor
Posted 26 May
PMI-controlled mannose meta…
By newseditor
Posted 26 May
Protein-membrane interactio…
By newseditor
Posted 26 May
Toward an interventional sc…
By newseditor
Posted 26 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar